Literature DB >> 30525581

Molecular Mechanism of Inhibition of Acid Ceramidase by Carmofur.

Alexey Dementiev1, Andrzej Joachimiak1, Ha Nguyen2,3, Alexei Gorelik4, Katalin Illes4, Saman Shabani5, Michael Gelsomino5, Eun-Young Erin Ahn6, Bhushan Nagar4, Ninh Doan6.   

Abstract

Human acid ceramidase (AC) is a lysosomal cysteine amidase, which has received a great deal of interest in recent years as a potential target for the development of new therapeutics against melanoma and glioblastoma tumors. Despite the strong interest in obtaining structural information, only the structures of the apo-AC enzyme in its zymogen and activated conformations are available. In this work, the crystal structure of AC in complex with the covalent carmofur inhibitor is presented. Carmofur is an antineoplastic drug containing an electrophilic carbonyl reactive group that targets the catalytic cysteine. This novel structural data explains the basis of the AC inhibition, provides insights into the enzymatic properties of the protein, and is a great aid toward the structure-based drug design of potent inhibitors for AC, providing the detailed mechanism, which has eluded the scientific community for more than 30 years, of carmofur's mysterious 5-fluorouracil-independent antitumor activity.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30525581      PMCID: PMC6863082          DOI: 10.1021/acs.jmedchem.8b01723

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  40 in total

1.  Oral carmofur in advanced gastrointestinal cancer.

Authors:  P Gröhn; E Heinonen; E Kumpulainen; H Länsimies; A Lantto; R Salmi; S Pyrhönen; S Numminen
Journal:  Am J Clin Oncol       Date:  1990-12       Impact factor: 2.339

2.  Acid ceramidase inhibition sensitizes human colon cancer cells to oxaliplatin through downregulation of transglutaminase 2 and β1 integrin/FAK-mediated signalling.

Authors:  Marko Klobučar; Petra Grbčić; Sandra Kraljević Pavelić; Nives Jonjić; Sarah Visentin; Mirela Sedić
Journal:  Biochem Biophys Res Commun       Date:  2018-06-21       Impact factor: 3.575

3.  [Anti-tumor effects of carmofur on human 5-FU resistant cells].

Authors:  S Sato; T Ueyama; H Fukui; K Miyazaki; M Kuwano
Journal:  Gan To Kagaku Ryoho       Date:  1999-10

4.  Induction of oxidative stress by anticancer drugs in the presence and absence of cells.

Authors:  Chikako Yokoyama; Yuto Sueyoshi; Mika Ema; Yumi Mori; Kazuto Takaishi; Hisashi Hisatomi
Journal:  Oncol Lett       Date:  2017-09-14       Impact factor: 2.967

5.  Efficacy of oral adjuvant therapy after resection of colorectal cancer: 5-year results from three randomized trials.

Authors:  Junichi Sakamoto; Yasuo Ohashi; Chikuma Hamada; Marc Buyse; Tomasz Burzykowski; Pascal Piedbois
Journal:  J Clin Oncol       Date:  2004-02-01       Impact factor: 44.544

6.  Overview of the CCP4 suite and current developments.

Authors:  Martyn D Winn; Charles C Ballard; Kevin D Cowtan; Eleanor J Dodson; Paul Emsley; Phil R Evans; Ronan M Keegan; Eugene B Krissinel; Andrew G W Leslie; Airlie McCoy; Stuart J McNicholas; Garib N Murshudov; Navraj S Pannu; Elizabeth A Potterton; Harold R Powell; Randy J Read; Alexei Vagin; Keith S Wilson
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  2011-03-18

7.  Benzoxazolone carboxamides: potent and systemically active inhibitors of intracellular acid ceramidase.

Authors:  Daniela Pizzirani; Anders Bach; Natalia Realini; Andrea Armirotti; Luisa Mengatto; Inga Bauer; Stefania Girotto; Chiara Pagliuca; Marco De Vivo; Maria Summa; Alison Ribeiro; Daniele Piomelli
Journal:  Angew Chem Int Ed Engl       Date:  2014-11-13       Impact factor: 15.336

8.  Acid ceramidase is a novel drug target for pediatric brain tumors.

Authors:  Ninh B Doan; Ha S Nguyen; Andrew Montoure; Mona M Al-Gizawiy; Wade M Mueller; Shekar Kurpad; Scott D Rand; Jennifer M Connelly; Christopher R Chitambar; Kathleen M Schmainda; Shama P Mirza
Journal:  Oncotarget       Date:  2017-04-11

Review 9.  5-fluorouracil and cardiotoxicity: a review.

Authors:  Jaskanwal D Sara; Jasvinder Kaur; Ryan Khodadadi; Muneeb Rehman; Ronstan Lobo; Sakti Chakrabarti; Joerg Herrmann; Amir Lerman; Axel Grothey
Journal:  Ther Adv Med Oncol       Date:  2018-06-18       Impact factor: 8.168

10.  Acid ceramidase and its inhibitors: a de novo drug target and a new class of drugs for killing glioblastoma cancer stem cells with high efficiency.

Authors:  Ninh B Doan; Hisham Alhajala; Mona M Al-Gizawiy; Wade M Mueller; Scott D Rand; Jennifer M Connelly; Elizabeth J Cochran; Christopher R Chitambar; Paul Clark; John Kuo; Kathleen M Schmainda; Shama P Mirza
Journal:  Oncotarget       Date:  2017-11-07
View more
  16 in total

1.  Design, Synthesis, and Biological Evaluation of a Series of Oxazolone Carboxamides as a Novel Class of Acid Ceramidase Inhibitors.

Authors:  Samantha Caputo; Simona Di Martino; Vincenzo Cilibrasi; Piero Tardia; Marco Mazzonna; Debora Russo; Ilaria Penna; Maria Summa; Sine Mandrup Bertozzi; Natalia Realini; Natasha Margaroli; Marco Migliore; Giuliana Ottonello; Min Liu; Peter Lansbury; Andrea Armirotti; Rosalia Bertorelli; Soumya S Ray; Renato Skerlj; Rita Scarpelli
Journal:  J Med Chem       Date:  2020-12-08       Impact factor: 7.446

2.  Genetic and pharmacological inhibition of acid ceramidase prevents asymmetric cell division by neosis.

Authors:  Shai White-Gilbertson; Ping Lu; James S Norris; Christina Voelkel-Johnson
Journal:  J Lipid Res       Date:  2019-04-15       Impact factor: 5.922

3.  Targeting Acid Ceramidase Inhibits Glioblastoma Cell Migration through Decreased AKT Signaling.

Authors:  Cyntanna C Hawkins; Amber B Jones; Emily R Gordon; Sarah E Williford; Yuvika Harsh; Julia K Ziebro; Catherine J Landis; Sajina Gc; David K Crossman; Sara J Cooper; Sasanka Ramanadham; Ninh Doan; Anita B Hjelmeland
Journal:  Cells       Date:  2022-06-09       Impact factor: 7.666

4.  Inhibiting eukaryotic ribosome biogenesis.

Authors:  Dominik Awad; Michael Prattes; Lisa Kofler; Ingrid Rössler; Mathias Loibl; Melanie Pertl; Gertrude Zisser; Heimo Wolinski; Brigitte Pertschy; Helmut Bergler
Journal:  BMC Biol       Date:  2019-06-10       Impact factor: 7.431

5.  Ebselen, Disulfiram, Carmofur, PX-12, Tideglusib, and Shikonin Are Nonspecific Promiscuous SARS-CoV-2 Main Protease Inhibitors.

Authors:  Chunlong Ma; Yanmei Hu; Julia Alma Townsend; Panagiotis I Lagarias; Michael Thomas Marty; Antonios Kolocouris; Jun Wang
Journal:  ACS Pharmacol Transl Sci       Date:  2020-10-09

6.  Targeting Acid Ceramidase to Improve the Radiosensitivity of Rectal Cancer.

Authors:  Rachael E Clifford; Naren Govindarajah; David Bowden; Paul Sutton; Mark Glenn; Mahnaz Darvish-Damavandi; Simon Buczacki; Ultan McDermott; Zdzislaw Szulc; Besim Ogretmen; Jason L Parsons; Dale Vimalachandran
Journal:  Cells       Date:  2020-12-15       Impact factor: 6.600

Review 7.  Recent Progress in the Drug Development Targeting SARS-CoV-2 Main Protease as Treatment for COVID-19.

Authors:  Wen Cui; Kailin Yang; Haitao Yang
Journal:  Front Mol Biosci       Date:  2020-12-04

Review 8.  Sphingomyelinases and Liver Diseases.

Authors:  Naroa Insausti-Urkia; Estel Solsona-Vilarrasa; Carmen Garcia-Ruiz; Jose C Fernandez-Checa
Journal:  Biomolecules       Date:  2020-10-30

Review 9.  Sphingolipid Metabolism in Glioblastoma and Metastatic Brain Tumors: A Review of Sphingomyelinases and Sphingosine-1-Phosphate.

Authors:  Cyntanna C Hawkins; Tomader Ali; Sasanka Ramanadham; Anita B Hjelmeland
Journal:  Biomolecules       Date:  2020-09-23

Review 10.  Repurposing anticancer drugs for the management of COVID-19.

Authors:  Khalid El Bairi; Dario Trapani; Angelica Petrillo; Cécile Le Page; Hanaa Zbakh; Bruno Daniele; Rhizlane Belbaraka; Giuseppe Curigliano; Said Afqir
Journal:  Eur J Cancer       Date:  2020-09-22       Impact factor: 9.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.